Icon PLC
ICLR
164.08
+2.39
+1.48%
Icon PLC
US · ICLR
#1235 by market cap
Listed 1970
164.08
+2.39
+1.48%
Live - 5344 symbols - heartbeat 109s ago
· 2026-10-07 19:54
After-hours
164.08
0.00%
- Market cap
- 12.66B
- P/E (TTM)i
- 252.43
- P/Bi
- 1.35
- EPSi
- 2.90
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on ICLR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.99, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.76% YoY
Margins
- Gross margin
- 26.37%
- Operating margin
- 12.27%
- Net margin
- 2.78%
Key ratios & quality
- Enterprise valuei
- 15.45B
- Altman Z-Scorei
- 1.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.60B | 2.81B | 2.80B | 5.48B | 7.74B | 8.05B | 8.19B | 8.25B |
| Gross profit | 777.56M | 831.70M | 817.41M | 1.51B | 2.21B | 2.35B | 2.37B | 2.18B |
| Selling & admin expenses | 325.79M | 332.66M | 342.45M | 585.33M | 778.75M | 768.56M | 728.35M | 780.14M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 385.85M | 437.49M | 408.83M | 607.90M | 866.08M | 994.23M | 1.15B | 1.01B |
| Pretax profit | 364.61M | 426.99M | 381.21M | 196.68M | 567.85M | 572.98M | 803.76M | 252.47M |
| Tax | 41.96M | 51.13M | 47.88M | 41.33M | 59.41M | 18.39M | 64.63M | 23.13M |
| Net profit | 322.66M | 375.86M | 332.96M | 153.19M | 505.30M | 554.21M | 739.13M | 229.34M |
| Basic EPS | 6 | 7 | 6 | 2 | 6 | 7 | 9 | 3 |
| Diluted EPS | 5.89 | 6.79 | 6.15 | 2.25 | 6.13 | 6.70 | 8.90 | 2.90 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.02B | 2.04B | 2.08B | 2.11B | 2.03B | 2.06B |
| Gross profit | 566.06M | 583.33M | 545.46M | 480.74M | 477.93M | 479.29M |
| Selling & admin expenses | 198.38M | 205.01M | 197.05M | 179.70M | 200.60M | 194.32M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 271.72M | 280.61M | 249.39M | 210.75M | 187.00M | 194.21M |
| Pretax profit | 181.16M | 182.84M | -271.39M | 159.85M | 127.56M | 92.20M |
| Tax | 20.35M | -20.67M | 12.79M | 10.66M | 22.81M | 19.62M |
| Net profit | 160.81M | 203.52M | -284.18M | 149.19M | 104.75M | 72.58M |
| Basic EPS | 2 | 3 | -4 | 2 | 1 | 1 |
| Diluted EPS | 1.99 | 2.56 | -3.67 | 1.93 | 1.36 | 0.94 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.33B | 1.62B | 2.10B | 2.94B | 3.23B | 3.29B | 3.28B | 3.50B |
| Cash & ST investments | 455.76M | 569.94M | 842.03M | 753.93M | 290.48M | 380.06M | 538.79M | 647.30M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 2.35B | 2.91B | 3.44B | 17.39B | 17.19B | 16.86B | 16.63B | 16.27B |
| Total current liabilities | 610.62M | 1.13B | 1.12B | 2.48B | 2.69B | 2.73B | 2.64B | 3.20B |
| Short-term debt | -- | 377.96M | 24.33M | 105.10M | 98.81M | 146.56M | 66.55M | 566.04M |
| Long-term debt | 349.26M | -- | 348.48M | 5.38B | 4.60B | 3.67B | 3.40B | 2.87B |
| Total liabilities | 999,974,000.00 | 1,289,457,000.00 | 1,585,370,000.00 | 9,320,263,000.00 | 8,687,315,000.00 | 7,653,337,000.00 | 7,193,468,000.00 | 7,076,398,000.00 |
| Total equity | 1.35B | 1.62B | 1.85B | 8.07B | 8.50B | 9.21B | 9.44B | 9.19B |
| Retained earnings | 888.33M | 1.11B | 1.26B | 1.42B | 1.82B | 2.40B | 2.64B | 2.12B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.42B | 3.31B | 3.41B | 3.50B | 3.61B | 3.75B |
| Cash & ST investments | 526.70M | 390.40M | 468.89M | 647.30M | 765.16M | 928.39M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 16.72B | 16.60B | 16.51B | 16.27B | 16.32B | 16.40B |
| Total current liabilities | 2.69B | 2.56B | 3.22B | 3.20B | 3.17B | 3.93B |
| Short-term debt | 29.76M | 29.76M | 529.76M | 566.04M | 529.76M | 1.28B |
| Long-term debt | 3.39B | 3.38B | 2.88B | 2.87B | 2.87B | 2.11B |
| Total liabilities | 7,222,142,000.00 | 7,047,203,000.00 | 7,172,644,000.00 | 7,076,398,000.00 | 7,018,726,000.00 | 7,022,158,000.00 |
| Total equity | 9.50B | 9.56B | 9.33B | 9.19B | 9.30B | 9.38B |
| Retained earnings | 2.63B | 2.56B | 2.31B | 2.12B | 2.23B | 2.30B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 268.64M | 412.54M | 568.04M | 829.14M | 563.32M | 1.16B | 1.29B | 1.04B |
| Depreciation & amortization | 65.92M | 61.55M | 66.13M | 314.99M | 569.51M | 585.95M | 488.50M | 383.00M |
| Free cash flow | 220.24M | 373.59M | 527.15M | 735.39M | 421.16M | 1.02B | 1.12B | 861.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -128.96M | -146.93M | -175.00M | 0 | -99.98M | 0 | -500.00M | -750.00M |
| Ending cash balance | 395.85M | 520.31M | 840.31M | 752.21M | 288.77M | 378.10M | 538.79M | 647.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 268.24M | 146.20M | -146.20M | 767.97M | -- | -- |
| Depreciation & amortization | 95.96M | 97.72M | -97.72M | 287.04M | -- | -- |
| Free cash flow | 239.33M | 113.92M | -113.92M | 622.66M | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -250.00M | -250.00M | 250.00M | -500.00M | -- | -- |
| Ending cash balance | 526.70M | 390.40M | 526.70M | 647.30M | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 25.35 | 25.16 | 19.16 | 3.09 | 6.10 | 6.90 | 8.44 | 2.45 |
| ROA %i | 14.34 | 14.22 | 10.48 | 1.47 | 2.92 | 3.58 | 4.67 | 1.38 |
| ROIC %i | 20.37 | 18.28 | 15.67 | 2.84 | 5.11 | 6.89 | 7.39 | 3.04 |
| 5-year avg ROE %i | 25.78 | 27.04 | 25.23 | 19.71 | 15.65 | 11.84 | 8.46 | 5.17 |
| EBIT margin %i | 14.57 | 15.69 | 14.09 | 5.30 | 10.04 | 11.52 | 12.99 | 5.34 |
| FCF / sales %i | 8.48 | 12.90 | 18.48 | 13.42 | 5.44 | 12.57 | 13.51 | 10.45 |
| Current ratioi | 2.18 | 1.44 | 1.87 | 1.19 | 1.20 | 1.20 | 1.24 | 1.10 |
| Quick ratioi | 2.12 | 1.40 | 1.82 | 1.14 | 1.15 | 1.16 | 1.19 | 1.06 |
| Debt / assetsi | 14.84 | 15.63 | 12.62 | 32.47 | 28.10 | 23.35 | 21.66 | 21.86 |
| LT debt / equityi | 25.79 | 4.73 | 22.12 | 68.68 | 55.67 | 41.16 | 37.46 | 32.52 |
| Interest coveragei | 28.00 | 33.16 | 30.28 | 3.10 | 3.71 | 3.01 | 5.22 | 2.34 |
| Revenue CAGR (3Y) %i | 18.12 | 18.97 | 16.74 | 28.29 | 40.26 | 42.27 | 14.32 | 2.15 |
| Net income CAGR (3Y) %i | 10.44 | 12.06 | 5.21 | -21.99 | 11.05 | 19.13 | 68.98 | -23.15 |
| FCF CAGR (3Y) %i | -1.34 | 19.93 | 15.93 | 49.47 | 4.08 | 24.62 | 15.01 | 26.97 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.01 | 8.30 | 6.27 | 2.45 | 1.84 | 0.45 |
| ROA %i | 4.49 | 4.73 | 3.56 | 1.38 | 1.05 | 0.26 |
| ROIC %i | 7.02 | 7.25 | 5.75 | 3.04 | 2.56 | 1.15 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 12.32 | 12.23 | 9.75 | 5.34 | 4.68 | 3.56 |
| FCF / sales %i | 12.91 | 12.23 | 11.90 | 10.45 | -- | 10.66 |
| Current ratioi | 1.27 | 1.29 | 1.06 | 1.10 | 1.14 | 0.95 |
| Quick ratioi | 1.21 | 1.24 | 1.02 | 1.06 | 1.09 | 0.92 |
| Debt / assetsi | 21.28 | 21.36 | 21.40 | 21.86 | 21.50 | 21.30 |
| LT debt / equityi | 37.14 | 36.81 | 32.18 | 32.52 | 32.02 | 23.60 |
| Interest coveragei | 5.54 | 5.77 | 4.69 | 2.34 | 2.05 | 1.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Provision of outsourced development services on a global basis to the pharmaceutical, biotechnology100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.